Advancing Alzheimer's Research Through Multiomics
In order to enable the most accurate early detection of Alzheimer's, AgenT is conducting what we believe to be one of the largest multiomics clinical study ever pursued in Alzheimer's research. We are collaborating with leading academic medical centers to conduct retrospective studies on hundreds of plasma samples to identify the patterns required to detect Alzheimer's and help validate AgenT’s products.
Our goal is to ensure that our testing platform is accessible to all. We aim to develop the clinical and health economic evidence required for FDA and other regulatory approvals, for inclusion in Alzheimer's screening guidelines, and to support reimbursement.
The objective of APOLLO study is to assess the performance of our multiomics blood test in retrospectively collected human plasma samples using Machine Learning to combine metabolomic and proteomic biomarkers, pre-identified in a brand-new rat model.
We are interested in collaborations to pursue innovative research opportunities and approaches that will impact early detection of Alzheimer's.